Literature DB >> 32258021

BAP1 Immunoreactivity Correlates with Gene Expression Class in Uveal Melanoma.

Thonnie Rose See1, Gustav Stålhammar1,2,3, Stephen Phillips1, Hans E Grossniklaus1.   

Abstract

BACKGROUND: Uveal melanoma (UM) is the most common intraocular tumour in adults. Currently there are different tests available to determine the risk of UM for metastasis, among which include BRCA1-associated protein-1 (BAP1) immunohistochemistry (IHC) and gene expression profiling (GEP). BAP1 is a deubiquitylating enzyme (DUB) that has tumour suppressor activity, the loss of which therefore is associated with higher risk for tumour growth and metastasis.
OBJECTIVES: To compare and correlate the prognostic significance of BAP1-IHC staining patterns and GEP in the prediction of UM's risk for metastasis.
METHODS: This is a retrospective chart review with prospective follow-up of patients with primary UM who underwent enucleation from the year 2008 to 2018. Clinical history, histopathologic findings, GEP classification, BAP1-IHC of the formalin-fixed paraffin-embedded tissues, and follow-up data for metastasis were collected and statistically analysed.
RESULTS: A total of 30 enucleated eyes with UM were included in the study. All class 1a tumours had high nuclear BAP1 expression and all class 2 had low nuclear BAP1 expression. Fifty percent of the class 1b tumours had low nuclear BAP1 expression. Among the tumours with low nuclear BAP1 expression, 68% developed metastasis, while 9% developed metastasis among high nuclear expression. Fifty-five percent developed metastasis in tumours with high cytoplasmic expression and 42% for low cytoplasmic expression. Predictive values for metastasis (positive predictive value, negative predictive value) are as follows: (1) nuclear BAP1-IHC (68%, 91%), (2) cytoplasmic BAP1-IHC (55%, 58%), and (3) GEP (73%, 80%). Nuclear BAP1-IHC and GEP had the same accuracy rate of 77% and cytoplasmic BAP1-IHC had an accuracy of 57%.
CONCLUSION: Low nuclear BAP1-IHC strongly correlates with GEP class 2 and was equally accurate in the prediction of metastasis.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  BAP1; Enucleated eyes; Gene expression profile; Uveal melanoma

Year:  2019        PMID: 32258021      PMCID: PMC7109388          DOI: 10.1159/000502550

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  25 in total

1.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.

Authors:  D E Jensen; M Proctor; S T Marquis; H P Gardner; S I Ha; L A Chodosh; A M Ishov; N Tommerup; H Vissing; Y Sekido; J Minna; A Borodovsky; D C Schultz; K D Wilkinson; G G Maul; N Barlev; S L Berger; G C Prendergast; F J Rauscher
Journal:  Oncogene       Date:  1998-03-05       Impact factor: 9.867

2.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

3.  Comparing the Prognostic Value of BAP1 Mutation Pattern, Chromosome 3 Status, and BAP1 Immunohistochemistry in Uveal Melanoma.

Authors:  Johannes A P van de Nes; Jasmin Nelles; Stefan Kreis; Claudia H D Metz; Thomas Hager; Dietmar R Lohmann; Michael Zeschnigk
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

4.  Genetic and clinico-pathologic analysis of metastatic uveal melanoma.

Authors:  Klaus G Griewank; Johannes van de Nes; Bastian Schilling; Iris Moll; Antje Sucker; Hojabr Kakavand; Lauren E Haydu; Marina Asher; Lisa Zimmer; Uwe Hillen; John F Thompson; Richard A Scolyer; Dirk Schadendorf; Rajmohan Murali
Journal:  Mod Pathol       Date:  2013-07-26       Impact factor: 7.842

5.  Correlation of Immunocytochemistry of BRCA1-associated Protein-1 (BAP1) With Other Prognostic Markers in Uveal Melanoma.

Authors:  Ben J Glasgow; Tara A McCannel
Journal:  Am J Ophthalmol       Date:  2018-03-09       Impact factor: 5.258

Review 6.  Molecular pathways mediating liver metastasis in patients with uveal melanoma.

Authors:  Silvin Bakalian; Jean-Claude Marshall; Patrick Logan; Dana Faingold; Shawn Maloney; Sebastian Di Cesare; Claudia Martins; Bruno F Fernandes; Miguel N Burnier
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

7.  Very long-term prognosis of patients with malignant uveal melanoma.

Authors:  Emma Kujala; Teemu Mäkitie; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

8.  BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma.

Authors:  Akeesha A Shah; T David Bourne; Rajmohan Murali
Journal:  Pathology       Date:  2013-12       Impact factor: 5.306

9.  BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.

Authors:  Katie A Matatall; Olga A Agapova; Michael D Onken; Lori A Worley; Anne M Bowcock; J William Harbour
Journal:  BMC Cancer       Date:  2013-08-05       Impact factor: 4.430

10.  Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing.

Authors:  H Kalirai; A Dodson; S Faqir; B E Damato; S E Coupland
Journal:  Br J Cancer       Date:  2014-07-24       Impact factor: 7.640

View more
  9 in total

1.  BAP1 Immunostain Status in Intraocular Biopsy Specimens for Uveal Melanoma Highly Correlates with Other Prognostic Markers.

Authors:  Cristiane M Ida; Jose Pulido; Patricia T Greipp; Joaquin J Garcia; Timothy W Olsen; Lauren Dalvin; Diva Regina Salomão
Journal:  Ocul Oncol Pathol       Date:  2021-11-15

2.  Loss of polycomb repressive complex 1 activity and chromosomal instability drive uveal melanoma progression.

Authors:  Mathieu F Bakhoum; Jasmine H Francis; Albert Agustinus; Ethan M Earlie; Melody Di Bona; David H Abramson; Mercedes Duran; Ignas Masilionis; Elsa Molina; Alexander N Shoushtari; Michael H Goldbaum; Paul S Mischel; Samuel F Bakhoum; Ashley M Laughney
Journal:  Nat Commun       Date:  2021-09-13       Impact factor: 17.694

3.  Long-term relative survival in uveal melanoma: a systematic review and meta-analysis.

Authors:  Gustav Stålhammar; Christina Herrspiegel
Journal:  Commun Med (Lond)       Date:  2022-03-01

Review 4.  Ubiquitin Carboxyl-Terminal Hydrolases and Human Malignancies: The Novel Prognostic and Therapeutic Implications for Head and Neck Cancer.

Authors:  Chao Rong; Ran Zhou; Shan Wan; Dan Su; Shou-Li Wang; Jochen Hess
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

5.  Nuclear expression of BAP-1 in transvitreal incisional biopsies and subsequent enucleation of eyes with posterior choroidal melanoma.

Authors:  Christina Herrspiegel; Anders Kvanta; Emma Lardner; Louise Ramsköld Cabaca; Jill Wells; Katarina Bartuma; Stefan Seregard; Gustav Stålhammar
Journal:  Br J Ophthalmol       Date:  2020-06-10       Impact factor: 4.638

6.  Estimation of the timing of BAP1 mutation in uveal melanoma progression.

Authors:  Ogul E Uner; Thonnie Rose O See; Eszter Szalai; Hans E Grossniklaus; Gustav Stålhammar
Journal:  Sci Rep       Date:  2021-04-26       Impact factor: 4.379

Review 7.  Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Authors:  Nuno Jorge Lamas; Arnaud Martel; Sacha Nahon-Estève; Samantha Goffinet; Adam Macocco; Corine Bertolotto; Sandra Lassalle; Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-12-25       Impact factor: 6.639

8.  Vasculogenic mimicry correlates to presenting symptoms and mortality in uveal melanoma.

Authors:  Shiva Sabazade; Viktor Gill; Christina Herrspiegel; Gustav Stålhammar
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-13       Impact factor: 4.553

9.  Correlation between BAP1 Localization, Driver Mutations, and Patient Survival in Uveal Melanoma.

Authors:  Yasemin C Cole; Yu-Zhi Zhang; Beatrice Gallo; Adam P Januszewski; Anca Nastase; David J Essex; Caroline M H Thaung; Victoria M L Cohen; Mandeep S Sagoo; Anne M Bowcock
Journal:  Cancers (Basel)       Date:  2022-08-25       Impact factor: 6.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.